VIDEO: New first-line treatment ‘potentially practice-changing’ in lung cancer subset
Click Here to Manage Email Alerts
MADRID — Hossein Borghaei, DO, MS, discussed results from the PAPILLON trial, which combined amivantamab and chemotherapy as first-line treatment for EGFR exon 20 insertion-mutated non-small cell lung cancer, in a video interview.
The study was presented at ESMO Congress.
With the widespread use of next-generation sequencing (NGS) panels in patients with NSCLC at the time of initial presentation, “we definitely see more and more of our patients with EGFR exon 20 insertions,” Borghaei, chief of the division of thoracic medical oncology at Fox Chase Cancer Center, said.
“This is the first time we have a bispecific antibody, amivantamab [Rybrevant, Janssen], combined with chemotherapy vs. chemotherapy for first-line treatment,” Borghaei told Healio.
“I think that this is something that could be potentially practice-changing because we definitely see this patient population in our clinics.”
Reference:
- Girard N, et al. Abstract LBA5. Presented at: European Society for Medical Oncology Congress; Oct. 20-24, 2023; Madrid.
Collapse
Healio Interviews
Click Here to Manage Email Alerts